Bill Lund­berg takes over the reins at Merus; For­mer Akcea COO Jef­frey Gold­berg takes the helm of Im­mu­ni­tas

Bill Lund­berg

→ Dutch biotech Merus, who struck up a $200 mil­lion bis­pe­cif­ic de­vel­op­ment deal with In­cyte in 2016,  is los­ing their CEO Ton Logten­berg. Mean­while, the com­pa­ny has nom­i­nat­ed Sven (Bill) Ante Lund­berg to be Logten­berg’s suc­ces­sor. Lund­berg, most re­cent­ly served as CSO at CRISPR Ther­a­peu­tics — help­ing es­tab­lish the com­pa­ny in Cam­bridge, MA and lead­ing the de­vel­op­ment of the com­pa­ny’s first clin­i­cal tri­al ap­pli­ca­tion. Pri­or to CRISPR, Lund­berg was the head of trans­la­tion­al med­i­cine at Alex­ion Phar­ma­ceu­ti­cals and CMO of Tal­i­gen Ther­a­peu­tics. His oth­er stints in­clude roles at Xan­thus/Anth­so­ma, Wyeth and Gen­zyme.

→ Ear­li­er this year, Hep B vac­cine mak­er Dy­navax Tech­nolo­gies was look­ing to un­load its im­muno-on­col­o­gy pro­gram, slash­ing jobs and de­vot­ing its re­sources to its vac­cine Hep­lisav-B. Now, the com­pa­ny has an­nounced the pro­mo­tion of Ryan Spencer to the role of CEO and David No­vack to the po­si­tion of pres­i­dent and COO. Spencer hopped aboard the com­pa­ny in 2006, and most re­cent­ly served as com­mer­cial vice pres­i­dent and since May 2019 has served as in­ter­im co-pres­i­dent with No­vack. No­vack joined Dy­navax in 2013. He pre­vi­ous­ly served in var­i­ous roles at No­var­tis

Jef­frey Gold­berg

→ Af­ter be­ing swept out with two oth­er top ex­ecs at Akcea, Jef­frey Gold­berg has found a new home at the helm of Im­mu­ni­tas Ther­a­peu­tics, where he will serve as the com­pa­ny’s CEO and di­rec­tor. Gold­berg will suc­ceed found­ing CEO, Christoph West­phal, who is mov­ing to the role of chair­man of the board of di­rec­tors. Dur­ing his time at Akcea, Gold­berg served as COO. Pri­or to that, he was the VP of busi­ness op­er­a­tions at Pro­teosta­sis Ther­a­peu­tics. His oth­er roles in­clude stints at Sanofi and Gen­zyme.

Ac­cel­er­a­tor Life Sci­ences start­up Lo­do Ther­a­peu­tics has tapped Dale Pfost to head the com­pa­ny as CEO and chair­man. Pfost draws from his ex­pe­ri­ence of pre­vi­ous­ly run­ning five biotech com­pa­nies — Mi­cro­Bio­me Ther­a­peu­tics, Acu­ity Phar­ma­ceu­ti­cals (lat­er merged to form OP­KO Health), Ox­ford Gly­co­Sciences, Or­chid Bio­Sciences and Re­cep­tor Bi­oLogix (lat­er ac­quired by Sym­phogen). Pfost was al­so a gen­er­al part­ner at VC firm Ad­vent Life Sci­ences. In ad­di­tion to Pfost’s ap­point­ment, Lo­do wel­comed Mer­ck vet Steve Col­let­ti as SVP of R&D, co-founder of Bloom Sci­ence An­tho­ny Co­lasin as SVP of busi­ness de­vel­op­ment, prin­ci­pal at BLL Part­ners Bar­bara Lind­heim as con­sult­ing vice pres­i­dent of strate­gic com­mu­ni­ca­tions and in­vestor re­la­tions and pres­i­dent of The Macken­zie Con­sult­ing Group Sara­jane Macken­zie as con­sult­ing vice pres­i­dent of hu­man re­sources and or­ga­ni­za­tion de­vel­op­ment.

Bone Ther­a­peu­tics — who saw their shares plum­met 26% af­ter hit­ting the brakes on a Phase III study of their cell ther­a­py for os­teonecro­sis — has snagged Miguel Forte to the helm of the com­pa­ny as CEO, suc­ceed­ing Thomas Lien­ard, who is hit­ting the ex­it. Forte makes the leap to the com­pa­ny af­ter serv­ing as the CEO of Zel­lu­na Im­munother­a­py and is cur­rent­ly serv­ing as CCO and chair of the com­mer­cial­iza­tion com­mit­tee of the In­ter­na­tion­al So­ci­ety of Cel­lu­lar Ther­a­py (ISCT). His pre­vi­ous ex­pe­ri­ence in­cludes roles at the EMA, UCB and Tx­Cell.

→ CRISPR-fo­cused Mam­moth Bio­sciences — co-found­ed by Jen­nifer Doud­na and backed by Tim Cook and Jeff Hu­ber — has ex­pand­ed its lead­er­ship team with the ap­point­ments of Pe­ter Nell to the role of CBO and head of ther­a­peu­tics and Ted Tisch as COO. Nell joins the with ex­pe­ri­ence from his time at Case­bia Ther­a­peu­tics and Bay­er Health­Care. Tisch joins the com­pa­ny af­ter a stint at Syn­thego, where he es­tab­lished the de­vel­op­ment, man­u­fac­tur­ing op­er­a­tions and com­mer­cial pro­gram of two CRISPR-based prod­uct lines.

Lantern Phar­ma — fo­cused on can­cer drug de­vel­op­ment with the help of AI and ge­nomics — has tapped David Mar­grave to the role of CFO and Kishor Gopal­das Bha­tia as CSO. Mar­grave joins the com­pa­ny af­ter serv­ing at BioN­u­merik Phar­ma­ceu­ti­cals, where he spent time in the roles of pres­i­dent, chief ad­min­is­tra­tive of­fi­cer and gen­er­al coun­sel. Bha­tia, whose re­search fo­cus­es on lym­phoma and EBV makes the hop over to Lantern from the di­rec­tor’s chair at Na­tion­al Can­cer In­sti­tute’s AIDS Ma­lig­nan­cy Pro­gram. 

Flag­ship-backed Cyg­nal Ther­a­peu­tics — which is fo­cused on ex­oneur­al bi­ol­o­gy — has ap­point­ed Elaine Caugh­ey to the role of CBO. Caugh­ey joins the com­pa­ny af­ter a stint as a con­sul­tant at The Black­stone Group. Her pre­vi­ous roles in­clude serv­ing as se­nior di­rec­tor of busi­ness de­vel­op­ment at Bio­gen and a role in busi­ness de­vel­op­ment and cor­po­rate ven­ture at CY­TYC Cor­po­ra­tion, lat­er ac­quired by Ho­log­ic

Joanne Beck Boston

Nim­bus Ther­a­peu­tics — who, back in Ju­ly, had Cel­gene, ahead of $74 bil­lion Bris­tol-My­ers buy­out, bag an op­tion for the com­pa­ny’s HPK1 in­hibitor pro­gram — has pro­mot­ed CMO An­nie Chen to be pres­i­dent of the com­pa­ny’s Tyk2 sub­sidiary, Nim­bus Lak­sh­mi. Along with her new role, Chen will still con­tin­ue her re­spon­si­bil­i­ties as CMO to the com­pa­ny. Chen has served in the role of CMO since 2015 and pri­or to her time at Nim­bus, was ex­ec­u­tive di­rec­tor of clin­i­cal re­search and sec­tion head of vac­cines at Mer­ck. Be­fore that, Chen held stints at Genen­tech and Cel­era Ge­nomics.

Boston Phar­ma­ceu­ti­cals — who, last Oc­to­ber, inked two big in-li­cens­ing deals with No­var­tis and GSK has wel­comed Joanne Beck as COO. Beck makes the hop over af­ter a stint as EVP of glob­al phar­ma­ceu­ti­cal de­vel­op­ment and op­er­a­tions at Cel­gene. In her new role, Beck will draw from ex­pe­ri­ence dur­ing her time at Shire — serv­ing as SVP of phar­ma­ceu­ti­cal de­vel­op­ment — Ab­bott’s Glob­al Phar­ma­ceu­ti­cal Op­er­a­tions, Ab­bott Vas­cu­lar, Genen­tech and Am­gen

Im­muneer­ing — whose cur­rent pipeline fo­cus­es on dis­eases such as can­cer cachex­ia and metas­ta­sis — has tapped Scott Bar­rett as CMO. Pri­or to join­ing the com­pa­ny, Bar­rett was the glob­al med­ical af­fairs lead for Tar­get­ed Ther­a­peu­tics at In­cyte Phar­ma­ceu­ti­cals. In ad­di­tion, he has al­so held stints at In­fin­i­ty Phar­ma­ceu­ti­cals, Ei­sai Phar­ma­ceu­ti­cals, and at the Janssen di­vi­sion of J&J.

Scott Bar­rett Im­muneer­ing

→ Neu­rode­gen­er­a­tive dis­ease-fo­cused E-Scape Bio has named Tony Ri­mac as CFO and Ann Ka­poun as SVP of R&D. Ri­mac joins the com­pa­ny from Chrono Ther­a­peu­tics, where he served as CFO and CBO. Pri­or to that, he served as CFO of Aldea Phar­ma­ceu­ti­cals, Adamas Phar­ma­ceu­ti­cals — lead­ing the com­pa­ny’s IPO — and Aerovance. Most re­cent­ly, Ka­poun served as SVP of trans­la­tion­al med­i­cine at On­coMed Phar­ma­ceu­ti­cals and has pre­vi­ous­ly held roles at ALZA and Scios, a bio­phar­ma unit of J&J.

→ Cell en­gi­neer­ing ser­vice provider Max­cyte — who re­cent­ly inked a deal with KSQ Ther­a­peu­tics has named Shru­ti Ab­ba­to as EVP of busi­ness de­vel­op­ment as the com­pa­ny con­tin­ues with a Phase I tri­al of its can­cer drug, MCY-M11. Pri­or to his new role at Max­cyte, Ab­ba­to was the VP of busi­ness de­vel­op­ment at treat­ment de­vel­op­er Cel­dara Med­ical and was the own­er of Per­spicere.

→ Not long af­ter seal­ing a li­cens­ing deal with Emory Uni­ver­si­ty, Neu­ro­trau­ma Sci­ences has wel­comed Todd Ver­doorn as VP of re­search and de­vel­op­ment. Ver­doorn, most re­cent­ly, served as CSO of Di­aMed­ica.

→ Months af­ter the FDA lift­ed its par­tial hold on Xen­cor’s CD123 x CD3 bis­pe­cif­ic, XmAb14045 — af­ter the drug caused one of two deaths —  the com­pa­ny has ap­point­ed Allen Yang to the role of SVP and CMO. In his new role, Yang will be re­spon­si­ble for lead­ing clin­i­cal de­vel­op­ment and strat­e­gy and over­see­ing op­er­a­tions for Xen­cor’s port­fo­lio of XmAb an­ti­body drug can­di­dates. Yang joins the com­pa­ny from Jazz Phar­ma­ceu­ti­cals, where he served as VP, head of clin­i­cal de­vel­op­ment and act­ing CMO. Be­fore Jazz, Yang held roles at Spec­trum Phar­ma­ceu­ti­cals and Am­gen — where he was the glob­al de­vel­op­ment leader for Arane­sp in on­col­o­gy and clin­i­cal re­search med­ical di­rec­tor for Blin­cy­to.

→ Af­ter re­cent­ly bag­ging an $85 mil­lion round, Zen­tal­is Phar­ma­ceu­ti­cals has tapped Melis­sa Ep­per­ly as CFO. Ep­per­ly makes the jump to Zen­tal­is af­ter a stint in the same role at PsiOxus Ther­a­peu­tics. Pri­or to that, she was the CFO and head of busi­ness de­vel­op­ment at R-Pharm US. Pre­vi­ous­ly, Ep­per­ly has held stints at An­chor­age Cap­i­tal Group, Gold­man Sachs, Bain & Com­pa­ny and Mor­gan Stan­ley

Michael Hef­fer­nan In­da­lo

Pfiz­er and My­lan an­nounced that for­mer CEO and pres­i­dent of Pfiz­er Ian Read and for­mer chair­man and CEO of The Gillette Com­pa­ny James Kilts will join the Vi­a­tris board of di­rec­tors up­on the com­ple­tion of the planned merg­er of My­lan and Up­john — which is ex­pect­ed to oc­cur mid-2020. 

Jen­nifer Cook — who was the CEO of can­cer test­ing start­up Grail, but stepped down for fam­i­ly health rea­sons — has joined the board of di­rec­tors of Neil Ku­mar-led Bridge­Bio.

Mil­len­do Ther­a­peu­tics — who, last Au­gust, merged with strug­gling fer­til­i­ty com­pa­ny Ova­Sciencehas wel­comed cur­rent CMO of Bio­Marin Ge­off Nichol to the com­pa­ny’s board of di­rec­tors. 

In­da­lo Ther­a­peu­tics — fo­cused on the de­vel­op­ment of in­te­grin an­tag­o­nists for pa­tients suf­fer­ing from se­ri­ous fi­brot­ic dis­eases such as id­io­path­ic pul­monary fi­bro­sis (IPF) and non­al­co­holic steato­hep­ati­tis (NASH) — has ap­point­ed for­mer CEO of Col­legium Phar­ma­ceu­ti­cal Michael Hef­fer­nan as chair­man to the board of di­rec­tors.

→ Life sci­ences in­dus­try group RI Bio has ap­point­ed cur­rent CEO, pres­i­dent and co-founder of Med­ley Ge­nomics Patrice Mi­los as chair­man of the board of di­rec­tors. In ad­di­tion, the board ap­point­ed two new mem­bers, Bank of Amer­i­ca SVP and pri­vate client ad­vi­sor with Guy Asado­ri­an and VP of busi­ness de­vel­op­ment for The Al­lied Group Bri­an But­ler.

Patrice Mi­los Ri Bio

Pathios’ search for small mol­e­cule drugs that hit “or­phan” GCPR has been backed by Canaan. The com­pa­ny bagged $8.8 mil­lion in Se­ries A fi­nanc­ing and brought on Stu­art Hugh­es as the com­pa­ny’s CEO. Pri­or to join­ing Pathios, Hugh­es served as a se­nior di­rec­tor at Ver­tex and be­fore that held a stint at Eli Lil­ly

David Meeks has hand­ed in his res­ig­na­tion as CEO to Ipsen and is mak­ing the leap across the At­lantic to head start­up Fer­Gene. The 30-year bio­phar­ma vet­er­an has trav­eled the world through­out his ca­reer. He spent a lit­tle more than 3 years at the helm of Paris-based Ipsen, ar­riv­ing af­ter a stint run­ning the on­col­o­gy di­vi­sion at Bax­al­ta be­fore it was snapped up by Shire (which was lat­er bought by Take­da). Be­fore that, he was the top com­mer­cial of­fi­cer at En­do­cyte and ear­li­er he com­plet­ed a glob­al stint at No­var­tis.

Biogen CEO Michel Vounatsos (via Getty Images)

With ad­u­canum­ab caught on a cliff, Bio­gen’s Michel Vounatsos bets bil­lions on an­oth­er high-risk neu­ro play

With its FDA pitch on the Alzheimer’s drug aducanumab hanging perilously close to disaster, Biogen is rolling the dice on a $3.1 billion deal that brings in commercial rights to one of the other spotlight neuro drugs in late-stage development — after it already failed its first Phase III.

The big biotech has turned to Sage Therapeutics for its latest deal, close to a year after the crushing failure of Sage-217, now dubbed zuranolone, in the MOUNTAIN study.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,300+ biopharma pros reading Endpoints daily — and it's free.

Pascal Soriot (AP Images)

As­traZeneca, Ox­ford on the de­fen­sive as skep­tics dis­miss 70% av­er­age ef­fi­ca­cy for Covid-19 vac­cine

On the third straight Monday that the world wakes up to positive vaccine news, AstraZeneca and Oxford are declaring a new Phase III milestone in the fight against the pandemic. Not everyone is convinced they will play a big part, though.

With an average efficacy of 70%, the headline number struck analysts as less impressive than the 95% and 94.5% protection that Pfizer/BioNTech and Moderna have boasted in the past two weeks, respectively. But the British partners say they have several other bright spots going for their candidate. One of the two dosing regimens tested in Phase III showed a better profile, bringing efficacy up to 90%; the adenovirus vector-based vaccine requires minimal refrigeration, which may mean easier distribution; and AstraZeneca has pledged to sell it at a fraction of the price that the other two vaccine developers are charging.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,300+ biopharma pros reading Endpoints daily — and it's free.

Jason Kelly, Ginkgo Bioworks CEO (Kyle Grillot/Bloomberg via Getty Images)

Af­ter Ko­dak de­ba­cle, US lends $1.1B to a syn­thet­ic bi­ol­o­gy com­pa­ny and their big Covid-19, mR­NA plans

In mid-August, as Kodak’s $765 million government-backed push into drug manufacturing slowly fell apart in national headlines, Ginkgo Bioworks CEO Jason Kelly got a message from his company’s government liaison: HHS wanted to know if they, too, might want a loan.

The government’s decision to lend Kodak three quarters of a billion dollars raised eyebrows because Kodak had never made drugs before. But Ginkgo, while not a manufacturing company, had spent the last decade refining new ways to produce materials inside cells and building automated facilities across Boston.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,300+ biopharma pros reading Endpoints daily — and it's free.

Jef­frey Hat­field takes over from Diego Mi­ralles as CEO of Vi­vid­ion; Drag­on­fly scores a new ex­ec with COO Alex Lu­gov­skoy

→ San Diego protein degradation startup Vividion Therapeutics has made a change at the top with Jeffrey Hatfield taking the helm as CEO, replacing Diego Miralles six months after Roche forked over $135 million to collaborate with Vividion on their small molecule degraders. Hatfield is chairman of the board at miRagen Therapeutics and previously held the CEO job at Zafgen and Vitae Pharmaceuticals. He also had a series of leadership roles at Bristol Myers Squibb from 1996-2004, including SVP, immunology and virology divisions.

The ad­u­canum­ab co­nun­drum: The PhI­II failed a clear reg­u­la­to­ry stan­dard, but no one is cer­tain what that means any­more at the FDA

Eighteen days ago, virtually all of the outside experts on an FDA adcomm got together to mug the agency’s Billy Dunn and the Biogen team when they presented their upbeat assessment on aducanumab. But here we are, more than 2 weeks later, and the ongoing debate over that Alzheimer’s drug’s fate continues unabated.

Instead of simply ruling out any chance of an approval, the logical conclusion based on what we heard during that session, a series of questionable approvals that preceded the controversy over the agency’s recent EUA decisions has come back to haunt the FDA, where the power of precedent is leaving an opening some experts believe can still be exploited by the big biotech.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

John Maraganore, Alnylam CEO (Scott Eisen/Bloomberg via Getty Images)

Al­ny­lam gets the green light from the FDA for drug #3 — and CEO John Maraganore is ready to roll

Score another early win at the FDA for Alnylam.

The FDA put out word today that the agency has approved its third drug, lumasiran, for primary hyperoxaluria type 1, better known as PH1. The news comes just 4 days after the European Commission took the lead in offering a green light.

An ultra rare genetic condition, Alnylam CEO John Maraganore says there are only some 1,000 to 1,700 patients in the US and Europe at any particular point. The patients, mostly kids, suffer from an overproduction of oxalate in the liver that spurs the development of kidney stones, right through to end stage kidney disease.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,300+ biopharma pros reading Endpoints daily — and it's free.

Bob Nelsen (Photo by Michael Kovac/Getty Images)

Bob Nelsen rais­es $800M and re­cruits a star-stud­ded board to build the 'Fox­con­n' of biotech

Bob Nelsen spent his pandemic spring in his Seattle home, talking on the phone with Luciana Borio, the scientist who used to run pandemic preparedness on the National Security Council, and fuming with her about the dire state of American manufacturing.

Companies were rushing to develop vaccines and antibodies for the new virus, but even if they succeeded, there was no immediate supply chain or infrastructure to mass-produce them in a way that could make a dent in the outbreak.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,300+ biopharma pros reading Endpoints daily — and it's free.

Carl Hansen, AbCellera CEO (University of British Columbia)

From a pair of Air Jor­dans to a $200M-plus IPO, Carl Hansen is craft­ing an overnight R&D for­tune fu­eled by Covid-19

Back in the summer of 2019, Carl Hansen left his post as a professor at the University of British Columbia to go full time as the CEO at a low-profile antibody shop he had founded called AbCellera.

As biotech CEOs go, even after a fundraise Hansen wasn’t paid a whole heck of a lot. He ended up earning right at $250,000 for the year. His compensation package included a loan — which he later paid back — and a pair of Air Jordan tennis shoes. His newly-hired CFO, Andrew Booth, got a sweeter pay packet than that — which included his own pair of Air Jordans.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

In fi­nal days at Mer­ck, Roger Perl­mut­ter bets big on a lit­tle-known Covid-19 treat­ment

Roger Perlmutter is spending his last days at Merck, well, spending.

Two weeks after snapping up the antibody-drug conjugate biotech VelosBio for $2.75 billion, Merck announced today that it had purchased OncoImmune and its experimental Covid-19 drug for $425 million. The drug, known as CD24Fc, appeared to reduce the risk of respiratory failure or death in severe Covid-19 patients by 50% in a 203-person Phase III trial, OncoImmune said in September.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,300+ biopharma pros reading Endpoints daily — and it's free.